AbCellera Biologics Inc. (NASDAQ:ABCL) Q1 2024 Earnings Conference Call May 7, 2024 5:00 PM ET Company Participants Tryn Stimart - Chief Legal & Compliance Officer Carl Hansen - President, Chief Executive Officer Andrew Booth - Chief Financial Officer Conference Call Participants Andrea Tan - Goldman Sachs Jacqueline Kisa - TD Securities Scott Schoenhaus - KeyBanc Stephen Willey - Stifel Operator Good afternoon and welcome to AbCellera's Q1, 2024 Business Update Conference Call. My name is Harry and I will ...

AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.14 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 12.50%. A quarter ago, it was expected that this company would post a loss of $0.14 per share when it actually produced a loss of $0.17, delivering a surprise of -21.43%.Over the last four quarters, the company ha ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _________________________________________________________ FORM 10-Q _________________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Numbe ...

NEWS RELEASE AbCellera Reports Q1 2024 Business Results 05/07/2024 VANCOUVER, British Columbia--(BUSINESS WIRE) -- AbCellera (Nasdaq: ABCL) today announced financial results for the first quarter of 2024. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. “We continue to execute on advancing our internal pipeline, completing capital investments in forward integration, and expanding strategic partnerships,” said Carl Hansen, Ph.D., founder and CEO of AbCe ...

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) and Biogen Inc. (Nasdaq: BIIB) have entered into a strategic collaboration to discover antibodies for a novel target that enables the delivery of biotherapeutics to the brain for indications in neuroscience. “ Delivering biologics across the blood brain barrier is one of the most important and long-standing problems in neuroscience,” said Murray McCutcheon, Ph.D., SVP, Partnering at AbCellera. “ We are excited to work with Biogen on thi ...

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced that its scientists will present four posters with data from its T-cell engager programs and platform at the American Association for Cancer Research (AACR) Annual Meeting 2024, to be held April 5 to 10 at the San Diego Convention Center. With its T-cell engager platform, AbCellera is expanding therapeutic opportunities for this modality by generating molecules with the potential for improved efficacy and safety profiles ...

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced that Peter Thiel has notified the Company of his intention to resign from the Company’s Board of Directors for personal reasons, effective March 7, 2024. “ AbCellera continues to expand the frontier of biotech, a nefariously difficult and vital field,” said Peter Thiel. “ I am proud to have helped them with their mission.” Mr. Thiel joined AbCellera’s Board of Directors in November 2020 and served as the Chairman of the ...

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the following investor conferences: 44th Annual TD Cowen Health Care Conference on Tuesday, March 5, 2024, at 11:50 a.m. Pacific Time (2:50 p.m. Eastern Time) KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on Wednesday, March 20, 2024, at 8:15 a.m. Pacific Time (11:15 a.m. Eastern Time) Live audio webcasts of each presentation may be accessed through l ...

AbCellera Biologics Inc. (NASDAQ:ABCL) Q4 2023 Results Conference Call February 20, 2024 5:00 PM ET Company Participants Tryn Stimart - Chief Legal & Compliance Officer Carl Hansen - President, CEO Andrew Booth - CFO Conference Call Participants Robyn Karnauskas - Truist Andrea Tan - Goldman Sachs Allison Bratzel - Piper Sandler Stephen Willey - Stifel Steven Mah - Cowen Evan Seigerman - BMO Operator Good afternoon. Thank you for attending AbCellera Biologics Inc. FY 2023 Earnings Results and Business Updat ...

AbCellera Biologics Inc. (ABCL) reported $9.18 million in revenue for the quarter ended December 2023, representing a year-over-year decline of 57.4%. EPS of -$0.17 for the same period compares to -$0.10 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $9.58 million, representing a surprise of -4.19%. The company delivered an EPS surprise of -21.43%, with the consensus EPS estimate being -$0.14.While investors scrutinize revenue and earnings changes year-over-year and how they com ...